Current Practice in Vitamin D Management in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

• Published in: Biology of blood and marrow transplantation 2019-10, Vol.25 (10), p.2079-2085
• Main Authors: Ros-Soto, J., Snowden, J.A., Salooja, N., Gilleece, M., Parker, A., Greenfield, D.M., Anthias, C., Alfred, A., Harrington, A., Peczynski, C., Peggs, K., Madrigal, A., Basak, G.W., Schoemans, H.
• Format: Article
• Language: English
• Subjects: Hematopoietic stem cell transplantation; Post-transplant complications; Supportive care; Survey; Vitamin D
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2019.06.015

•There are discrepancies in monitoring and replacement of vitamin D across stem cell transplant centers.•A specific cutoff for serum 25(OH)D3 to commence vitamin D therapy cannot be recommended.•The use of vitamin D therapy is warranted in patients following stem cell transplantation.•Recommendations are needed to harmonize management of vitamin D deficiency in stem cell transplantation. Beyond its impact on bone health, numerous studies have investigated the immune-regulatory properties of vitamin D and shown how its deficiency can affect outcomes in allogeneic hematopoietic stem cell transplantation (HSCT), particularly in acute or chronic graft-versus-host disease. This survey, carried out by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation (EBMT), describes the current clinical practice discrepancies across the EBMT HSCT programs. We therefore recommend the development of evidence-based guidelines to standardize evaluation criteria and to harmonize the management of vitamin D deficiency in patients undergoing allogeneic HSCT.